Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients

Table 3 Phase III milestone trials of adjuvant therapy for gastric cancer after surgical resection and information of elderly patients

Publication	Trials	Patient eligibility	Successful regimens as adjuvant therapy	Adjuvant effect	Median	Range	Proportion of elderly patients (70 years old or over)	Ref.	Country
2001	INT-116	Pathological stage IB/II/III/IVM0	Surgery + Chemo (5-FU/LV)-Radiation (45Gy)	9% at 3 years	60	25-87	No information	[31]	USA
			Surgery alone		59	23-80
2006	MAGIC	Clinical stage II or more (M0)	Surgery + perioperative EPI/CDDP/5-FU (ECF)	13.6% at 5 years	62	29-85	20.4%	[32]	UK
			Surgery alone		62	23-81	21.3%
2007	ACTS-GC	Pathological stage II/IIIA/IIIB	Surgery + S1	10% at 3 years	63	27-80	25.9%	[34]	Japan
			Surgery alone		63	33-80	22.6%